Short answer
Xenon Pharmaceuticals Inc. (XENE) filed an 8-K current report with the SEC on February 27, 2026 reporting Item 8.01 (Other Events). ATM program refreshed with $400M capacity via new prospectus supplement filed Feb 27, 2026, superseding prior prospectus.
Xenon Pharmaceuticals Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ATM program refreshed with $400M capacity via new prospectus supplement filed Feb 27, 2026, superseding prior prospectus
- Already sold $291M under existing Sales Agreement, leaving meaningful remaining capacity under the new $400M shelf
- Sales agents are Jefferies and Stifel; shares sold at-market on an ongoing, opportunistic basis: continuous dilution risk for existing holders
- Backed by S-3 shelf registration (File No. 333-281451) filed Aug 2024, giving XENE flexible, rapid access to equity capital markets
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Xenon Pharmaceuticals Inc. 8-K filings
Get the next XENE 8-K as it lands
Follow XENE for push alerts, or ask the research agent what this filing means.